Apellis Pharmaceuticals Inc (APLS) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $21.64
• Market Cap: $2.71B
• P/E Ratio: 59.50
• EPS: $0.36
• 52-Week High: $30.48
• 52-Week Low: $16.10

Market Sentiment

Apellis Pharmaceuticals Inc currently has a Neutral sentiment score of 0.05.

About Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc. is a forward-looking clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focusing on the development of novel therapeutic compounds targeting the complement system to treat autoimmune and inflammatory diseases. The company's innovative pipeline, underscored by its flagship asset, aims to revolutionize treatment options for patients with complex conditions, highlighting Apellis' commitment to delivering transformative therapies. As a signific...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Apellis Pharmaceuticals Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does APLS pay dividends?

Apellis Pharmaceuticals Inc (APLS) does not currently pay a regular dividend.

What is APLS's P/E ratio?

Apellis Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 59.50.

What is APLS's market cap?

Apellis Pharmaceuticals Inc (APLS) has a market capitalization of $2.71B with a current stock price of $21.64.